A U.S. Food and Drug Administration advisory panel voted 11-3 on July 23 to place the peptide BPC-157 on the compounding list. The decision signals a major regulatory shift for the unregulated $1.2 billion peptide market. Hims & Hers Health (HIMS) stock rose 4.2% in after-hours trading on the news.
BPC-157, a synthetic peptide derived from human gastric juice, has been marketed for decades for tissue repair and gut health. It lacks FDA approval. The panel’s vote, while non-binding, opens a legal pathway for compounding pharmacies to produce it under prescription.
Telehealth firms, including Hims, have lobbied for this outcome. Their argument: peptides can be safely prescribed with guardrails. The FDA is expected to finalize the rule by Q4 2026. Analysts at Citi estimate the addressable U.S. market for compounded BPC-157 at $800 million annually by 2028.
| Metric | Hims (HIMS) | Industry Peer Avg |
|---|---|---|
| Telehealth subscribers (Q2 2026) | 2.4 million | 1.1 million |
| Compounding pharmacy partners | 14 | 6 |
| Peptide R&D spend (FY2025) | $42 million | $18 million |
Hims already offers compounding services for hormones and dermatology. Integrating BPC-157 requires minimal incremental cost. The company’s existing telehealth infrastructure—2.4 million subscribers—provides immediate distribution. Management stated in a July 24 investor call they expect to launch BPC-157 prescriptions within 90 days of final FDA approval.
Historical precedent supports the surge thesis. When the FDA placed compounded semaglutide on the shortage list in 2023, Hims stock rose 27% over the following six months. The BPC-157 decision is structurally similar: a popular, previously unregulated compound gains a legal channel.
Risks remain. The panel vote is advisory only. The full FDA could impose stricter guardrails, limiting compounding volumes. Competition is already forming: Ro, a direct competitor, announced a partnership with a major compounding pharmacy chain on July 24. Supply chain constraints for raw peptide materials could also limit Hims’ ability to scale.
Investors should watch two data points: the final FDA rule expected in November, and Hims’ Q3 earnings report in October, which will include initial peptide revenue projections. The peptide gold rush is real. Hims is the best-positioned pure-play to capture it.
💡 Frequently Asked Questions (FAQ)
- Q: What did the FDA advisory panel vote on regarding BPC-157?
- A: The panel voted 11-3 on July 23 to place the peptide BPC-157 on the compounding list, opening a legal pathway for compounding pharmacies to produce it under prescription.
- Q: How did Hims & Hers Health stock react to the news?
- A: Hims stock rose 4.2% in after-hours trading following the panel’s decision, reflecting investor optimism about the company’s potential to capitalize on the peptide market.
- Q: What is the estimated market size for compounded BPC-157?
- A: Analysts at Citi estimate the addressable U.S. market for compounded BPC-157 could reach $800 million annually by 2028.
- Q: How is Hims positioned to benefit from BPC-157 legalization?
- A: Hims has 2.4 million telehealth subscribers, 14 compounding pharmacy partners, and a $42 million peptide R&D budget, enabling low-cost integration and immediate distribution.
Extended Reading
Bloomberg reported on July 23 that telehealth firms, including Hims, submitted a joint letter to the FDA urging “legalization with guardrails.” The letter was signed by 14 companies representing 70% of the U.S. telehealth market. Reuters noted that the FDA panel specifically cited “patient demand” and “lack of serious adverse events in observational studies” as key factors in their vote. Yahoo Finance data shows retail investor interest in HIMS options spiked 340% on July 24.